Activation of KATP channels increases anticancer drug delivery to brain tumors and survival

European Journal of Pharmacology

Volumn 602, Issue 2-3, 2009, Pages 188-193

  Ningaraj, Nagendra S ^a   Sankpal, Umesh T ^a   Khaitan, Divya ^a   Meister, Edward A ^b   Vats, Trib ^c  

^a Curtis and Elizabeth Anderson Cancer Institute   (United States)

^b Clinical Research and Medical Education Department   (United States)

^c Backus Children's Hospital   (United States)

Author keywords

Blood brain barrier; Glioblastoma multiforme; Herceptin; Minoxidil sulfate; Potassium channel; Temozolomide

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBON 14; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLIBENCLAMIDE; MINOXIDIL SULFATE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; TEMOZOLOMIDE; TRASTUZUMAB; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTINEOPLASTIC AGENT; CARBON; DACARBAZINE; DRUG DERIVATIVE; MINOXIDIL; MINOXIDIL SULFATE ESTER; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAROTID ARTERY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GLIOMA; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; ANIMAL; APOPTOSIS; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; METABOLISM; METHODOLOGY; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARBON RADIOISOTOPES; CELL LINE, TUMOR; DACARBAZINE; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; KATP CHANNELS; MICE; MINOXIDIL; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS;

EID: 58149161532     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.056     Document Type: Article

References (42)

1. Agarwala S.S., and Kirkwood J.M. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5 (2000) 144-151
2. Agarwala S.S., Reyderman L., and Statkevich P. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma. Ann. Oncol. 9 (1998) 139
3. Asotra K., Ningaraj N., and Black K.L. Measurement of blood-brain and blood-tumor barrier permeabilities with [14C]-labeled tracers. Methods Mol. Med. (2003) 177-190
4. Baker S.D., Wirth M., Statkevich P., Reidenberg P., Alton K., Sartorius S.E., Dugan M., Cutler D., Batra V., Grochow L.B., Donehower R.C., and Rowinsky E.K. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. 5 (1999) 309-317
5. Black K.L., and Ningaraj N.S. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 11 (2004) 165-173
6. Black K.L., and Ningaraj N. Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor (2005), PCT, U.S.
7. Bland J.M. An introduction to medical statistics. 3rd Edition ed. (2003), Oxford University Press, London
8. Bocangel D.B., Finkelstein S., Schold S.C., Bhakat K.K., Mitra S., and Kokkinakis D.M. Multifaceted resistance of gliomas to temozolomide. Clin. Cancer Res. 8 (2002) 2725-2734
9. Brayden J.E. Functional roles of KATP channels in vascular smooth muscle. Clin. Exp. Pharmacol. Physiol. 29 (2002) 312-316
10. Cobbs C.S., Brenman J.E., Aldape K.D., Bredt D.S., and Israel M.A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 55 (1995) 727-730
11. Darkes M.J.M., Plosker G.L., and Jarvis B. Temozolomide a review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers. Am. J. Cancer 1 (2002) 55-80
12. Fidler I.J., Yano S., Zhang R.D., Fujimaki T., and Bucana C.D. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 3 (2002) 53-57
13. Forseen S.E., Potti A., Koka V., Koch M., Fraiman G., and Levitt R. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors. Anticancer Res. 22 (2002) 1599-1602
14. Friedman H.S., Kerby T., and Calvert H. Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 6 (2000) 2585-2597
15. Fuller G.N., and Bigner S.H. Amplified cellular oncogenes in neoplasms of the human central nervous system. Mutat. Res. 276 (1992) 299-306
16. Fung L.K., Shin M., Tyler B., Brem H., and Saltzman W.M. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm. Res. 13 (1996) 671-682
17. Hashizume K., and Black K.L. Increased endothelial vesicular transport correlates with increased blood-tumor barrier permeability induced by bradykinin and leukotriene C4. J. Neuropathol. Exp. Neurol. 61 (2002) 725-735
18. Heimberger A.B., Archer G.E., McLendon R.E., Hulette C., Friedman A.H., Friedman H.S., Bigner D.D., and Sampson J.H. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin. Cancer Res. 6 (2000) 4148-4153
19. Hirose Y., Berger M.S., and Pieper R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 61 (2001) 1957-1963
20. Jaeckle K.A., Hess K.R., Yung W.K., Greenberg H., Fine H., Schiff D., Pollack I.F., Kuhn J., Fink K., Mehta M., Cloughesy T., Nicholas M.K., Chang S., and Prados M. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 21 (2003) 2305-2311
21. Kanzawa T., Bedwell J., Kondo Y., Kondo S., and Germano I.M. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J. Neurosurg. 99 (2003) 1047-1052
22. Kitazono T., Faraci F.M., Taguchi H., and Heistad D.D. Role of potassium channels in cerebral blood vessels. Stroke 26 (1995) 1713-1723
23. Liu L., Taverna P., Whitacre C.M., Chatterjee S., and Gerson S.L. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin. Cancer Res. 5 (1999) 2908-2917
24. Ma J., Pulfer S., Li S., Chu J., Reed K., and Gallo J.M. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 61 (2001) 5491-5498
25. Morimoto T., Aoyagi M., Tamaki M., Yoshino Y., Hori H., Duan L., Yano T., Shibata M., Ohno K., Hirakawa K., and Yamaguchi N. Increased levels of tissue endostatin in human malignant gliomas. Clin. Cancer Res. 8 (2002) 2933-2938
26. Ningaraj N.S., Rao M., Hashizume K., Asotra K., and Black K.L. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J. Pharmacol. Exp. Ther. 301 (2002) 838-851
27. Ningaraj N.S., Rao M., and Black K.L. Calcium-dependent potassium channels as a target protein for modulation of the blood-brain tumor barrier. Drug News Perspect. 16 (2003) 291-298
28. Ningaraj N.S., Rao M.K., and Black K.L. Adenosine 5′-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res. 63 (2003) 8899-8911
29. Ohno K., Pettigrew K.D., and Rapoport S.I. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am. J. Physiol. 235 (1978) H299-H307
30. Ostermann S., Csajka C., Buclin T., Leyvraz S., Lejeune F., Decosterd L.A., and Stupp R. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin. Cancer Res. 10 (2004) 3728-3736
31. Panther L.A., Baumbach G.L., Bigner D.D., Piegors D., Groothuis D.R., and Heistad D.D. Vasoactive drugs produce selective changes in flow to experimental brain tumors. Ann. Neurol. 18 (1985) 712-715
32. Pardridge W.M. Drug targeting, drug discovery, and brain drug development. Brain drug targeting: The future of brain drug development (2001), Cambridge University Press, Cambridge 1-13
33. Patel M., McCully C., Godwin K., and Balis F.M. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J. Neurooncol. 61 (2003) 203-207
34. Pegg A.E., Dolan M.E., and Moschel R.C. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol. 51 (1995) 167-223
35. Pegram M.D., and Slamon D.J. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin. Oncol. 26 (1999) 89-95
36. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer 2 (2002) 83-90
37. Sattiraju S., Reyes S., Kane G.C., and Terzic A. K(ATP) channel pharmacogenomics: from bench to bedside. Clin. Pharmacol. Ther. 83 (2008) 354-357
38. Schoch H.J., Fischer S., and Marti H.H. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 125 (2002) 2549-2557
39. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., Pica A., Maillard I., Maeder P., Meuli R., Janzer R., Pizzolato G., Miralbell R., Porchet F., Regli L., de Tribolet N., Mirimanoff R.O., and Leyvraz S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20 (2002) 1375-1382
40. Tsang L.L., Quarterman C.P., Gescher A., and Slack J.A. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother. Pharmacol. 27 (1991) 342-346
41. Warnke P.C., Molnar P., Bigner D.D., Heistad D.H., and Groothuis D.R. Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas. Neurology 37 (1987) 1870-1873
42. Yokoshiki H., Sunagawa M., Seki T., and Sperelakis N. ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells. Am. J. Physiol. 274 (1998) C25-C37